These feedback loops are far more interconnected than we previously realized.
At the intersection of molecular biology and human suffering, a team spanning three institutions has drawn what may be the most detailed map yet of how the immune system governs itself. Using CRISPR to silence thousands of genes at once, researchers discovered that the molecular switches controlling T cell behavior are not isolated levers but deeply entangled nodes in a web of mutual influence — a finding that reframes how scientists understand autoimmune disease. Where medicine once saw separate conditions with separate causes, this map suggests a shared architecture of vulnerability.
- Autoimmune diseases like lupus and multiple sclerosis have long resisted unified explanation — this research suggests the answer may lie not in individual broken genes, but in disruptions to a shared regulatory network.
- By silencing over a thousand transcription factors simultaneously, scientists uncovered that just 10 regulators control all three of the most critical T cell genes at once — a density of connection no one anticipated.
- The network behaves less like a chain of command and more like a subway system: knock out one hub, and distant lines feel the disruption, which explains why different mutations can produce the same disease.
- Feedback loops throughout the network — where gene A regulates gene B, which in turn regulates gene A — mean the system is self-reinforcing, making both its stability and its failure modes more complex than previously modeled.
- The map now serves as a blueprint for drug development, pointing researchers toward specific regulatory nodes that, if targeted precisely, could restore immune balance without dismantling the system entirely.
A collaboration between Gladstone Institutes, UC San Francisco, and Stanford School of Medicine has produced something immunologists have long sought: a working diagram of how T cells regulate themselves. Using CRISPR to disrupt thousands of genes simultaneously, the team mapped which transcription factors — the molecular switches that activate or silence other genes — control the behavior of these critical immune cells. The findings, published in Nature Genetics, revealed a degree of interconnectedness that surprised the researchers themselves.
Postdoctoral fellow Jacob Freimer reframed the central question. Rather than asking what happens when a gene is removed, he asked which genes are doing the controlling. His team focused on three genes central to T cell function — IL2RA, IL-2, and CTLA4 — and found that among 117 regulators affecting at least one of them, 10 controlled all three at once. The network was far denser than expected.
The architecture grew stranger still upon closer inspection. Key transcription factors were simultaneously regulating others while being regulated themselves, forming feedback loops throughout the system. The researchers compared it not to a linear chain but to the interlocking hubs of a subway map — a structure where disruption at one point sends ripples in multiple directions.
This topology offered a new lens on autoimmune disease. Many of the genes falling under these regulators were already linked to conditions like lupus, rheumatoid arthritis, and multiple sclerosis. The map suggested that different mutations in different genes could converge on the same disease outcome precisely because those genes share a regulatory home. Senior author Alex Marson described the work as an instruction manual for immune cell function — and more practically, a guide to where therapeutic intervention might restore the balance when the system breaks down.
A team of researchers working across three institutions—Gladstone Institutes, UC San Francisco, and Stanford School of Medicine—has produced what amounts to a wiring diagram of the immune system. Using CRISPR gene editing to disrupt thousands of genes at once, they mapped how transcription factors—the molecular switches that turn other genes on and off—control the behavior of T cells, the white blood cells that fight infections and cancer. The work, published in Nature Genetics, reveals a level of interconnectedness that surprised even the scientists who conducted it.
For years, immunologists have known that when T cells activate, the levels of thousands of proteins inside them shift in coordinated ways. These proteins don't operate in isolation; changes in one ripple outward to affect others. Scientists have tried to map these relationships before, but their approach was limited. They would remove one gene at a time and watch what happened downstream—a painstaking method that only captured part of the picture. Jacob Freimer, a postdoctoral fellow in the labs of Alex Marson and Jonathan Pritchard, wanted to flip the perspective. Instead of asking what happens when you remove a gene, he asked: what genes are controlling the ones we know matter most?
Freimer and his team focused on three genes that play central roles in T cell function: IL2RA, IL-2, and CTLA4. Using CRISPR, they systematically disrupted more than a thousand transcription factors and measured which ones affected these three target genes. The results were striking. Among 117 regulators that controlled at least one of the three genes, 39 controlled two of them, and 10 controlled all three simultaneously. The connectivity was far denser than anticipated.
But the surprise deepened when the researchers looked at how these regulators related to each other. The transcription factor IRF4, for example, altered the activity of 9 other regulators while itself being regulated by 15 others. Many of the regulators controlled each other in what scientists call feedback loops—situations where gene A regulates gene B, and gene B in turn regulates gene A. These loops appeared throughout the network, creating a system of mutual influence that resembled, as the researchers noted, the interconnected hubs of a subway map rather than a simple linear chain.
The practical implications became clear when the team examined which genes fell under the control of these regulators. A striking number were already known to be associated with autoimmune diseases: multiple sclerosis, lupus, rheumatoid arthritis. The map suggested an explanation for a long-standing puzzle in immunology. Different genetic mutations in different genes could lead to the same disease because those genes were wired into the same regulatory network. Disrupt the network at different points, and you get the same outcome.
Alex Marson, director of the Gladstone-UCSF Institute of Genomic Immunology and a senior author of the study, described the work as creating an instruction manual for how human immune cells function. More than that, it offered a blueprint for engineering them—for understanding which genes need to work properly together to keep the immune system in balance, and which ones might be targeted by drugs to restore that balance when it breaks down. The map doesn't solve autoimmune disease, but it shows where to look and what to look for.
Citas Notables
These results help us flesh out a systematic network map that can serve as an instruction manual for how human immune cells function and how we can engineer them for our benefit.— Alex Marson, MD, PhD, director of the Gladstone-UCSF Institute of Genomic Immunology
It appears that these kinds of feedback loops and regulatory networks are much more interconnected than we previously realized.— Jacob Freimer, PhD, first author of the study
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that these regulators control each other? Couldn't you just target one gene and fix the problem?
Because the system is built on feedback. If you shut down one regulator, others compensate. The network adapts. Understanding the loops tells you which genes are truly central and which are peripheral—where a drug would actually stick.
So the surprise was how tangled it all is?
Exactly. They expected some overlap. They found that ten transcription factors all control the same three genes. It's not a hierarchy—it's a web. That changes how you think about disease.
And that explains why different mutations cause the same disease?
Right. If you have a mutation in gene A or gene B, but both A and B feed into the same regulatory hub, you end up with the same broken outcome. The disease isn't about which gene failed—it's about which network failed.
What happens next? Do they start testing drugs?
This is the foundation. Now they know which gene networks to target. The next phase is finding molecules that can modulate these networks without breaking everything else. That's the real work.